Early outcomes from a new multidisciplinary cardiometabolic clinic: real‐world experience in lowering low‐density lipoprotein cholesterol

This study presents real-world data on low-density lipoprotein cholesterol (LDL-C) management in the first 200 patients seen at a new multidisciplinary cardiometabolic clinic from January 2023, with follow-up until April 2024. The cohort had a mean ± standard deviation age of 52 ± 14 years, 51% were male, 69 (35%) had familial hypercholesterolaemia and 66 (33%) had cardiovascular disease. Lipid-lowering therapies were escalated in 120 (60%) patients. Median low-density lipoprotein cholesterol level decreased with initiation of evolocumab (69%), inclisiran (56%), statin (45%) and ezetimibe (21%). In patients with a history of statin intolerance, 19 (43%) re-initiated or increased statin dose.